CITIUS ONCOLOGY, INC. - Form 8-K Summary
Business Context and Reporting Period
Citius Oncology, Inc. (Nasdaq: CTOR), a Delaware corporation, filed this Current Report on Form 8-K on June 26, 2025. The report addresses a specific regulatory event regarding the company's listing status on The Nasdaq Capital Market.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to a notification of regulatory compliance.
Material Changes
The primary material event reported is the resolution of a listing deficiency. The company received written notice from Nasdaq confirming that it regained compliance with Listing Rule 5550(a)(2). This compliance was achieved because the closing bid price of the Company's common stock remained at or above $1.00 per share for 12 consecutive trading days between June 6, 2025, and June 24, 2025. Nasdaq has officially closed this matter.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies beyond the resolution of the specific listing compliance issue.
Key Facts for Investor Verification
- Confirm the current trading price of CTOR remains above the $1.00 minimum bid price requirement.
- Verify that no new delisting notices or compliance issues have been issued by Nasdaq subsequent to June 26, 2025.
- Review the company's most recent 10-Q or 10-K filings for actual financial performance data, as this 8-K contains none.